Initial studies have demonstrated the therapeutic efficacy for cancer treatment of in vivo transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir (GCV) treatment. However, recent studies have questioned the validity of this approach. Using retroviral vector-producing cells (VPC) as a source for in vivo gene transfer, we evaluated the efficacy of in vivo transduction of malignant cells using three different tumor cell models: B16 murine and IIB-MEL-LES human melanomas and a C6 rat glioblastoma. In vitro studies showed a bystander effect only in C6 cells. In vivo studies showed an inhibition of tumor growth in the two melanoma models when tumor cells were coinjected with VPC-producing retroviral vectors carrying the herpes simplex virus thymidine kinase gene, followed by GCV treatment; however, 100% of mice developed tumors in both models. Under similar experimental conditions, 70% (7 of 10) of syngeneic rats completely rejected stereotactically transferred C6 tumor cells; most of them (5 of 10) showed a prolonged survival. Treating established C6 tumors with VPC-producing retroviral vectors carrying the herpes simplex virus thymidine kinase gene and GCV led to the cure of 33% (4 of 12) of the animals. Rats that rejected tumor growth developed an antitumor immune memory, leading to a rejection of a stereotactic contralateral challenge with parental cells. The immune infiltrate, which showed the presence of T lymphocytes, macrophages, and polymorphonuclear cells at the site of the first injection and mainly T lymphocytes and macrophages at the site of tumor challenge, strengthened the importance of the immune system in achieving complete tumor rejection.
T he transfer of "suicide" genes into tumor cells that become sensitive to pharmacological agents is currently being studied as a treatment for different cancers. [1] [2] [3] [4] [5] Expression of the herpes simplex virus thymidine kinase (HSVtk) gene renders cells susceptible to the inert nucleoside analog ganciclovir (GCV), which becomes cytotoxic after phosphorylation by the viral enzyme. 6, 7 Different viral and nonviral vehicles have been used for HSVtk gene transfer, but retroviral vectors seem to be rather specific for cancer cells, because they are incorporated preferentially into the genome of dividing cells. 8 In vitro studies have demonstrated that the treatment of tumor cells expressing the HSVtk gene with GCV also led to the death of cells that do not express the gene. 1, 7, 9, 10 This "bystander" effect seems to be an important feature of the HSVtk/GCV system, because it is not possible to transduce 100% of tumor cells in situ using current vectors. 11 The exact mechanism by which this bystander effect takes place is under dispute. GCV toxic metabolites transferred through gap junctions between tumor cells [12] [13] [14] [15] and phagocytosis of apoptotic vesicles released by GCV-killed cells 16, 17 were postulated as possible mechanisms.
Whereas the bystander effect has been clearly demonstrated in vitro, the specific mechanisms of in vivo tumor regression following HSVtk/GCV treatment are not fully understood at this time. Initial studies reported that most of the rats injected stereotactically with 9L glioma cells and treated with the HSVtk/GCV system did not develop tumors. 9,18 -20 Moreover, the studies also showed the existence of a bystander effect in vivo. 7, 9, 21 These studies and other evidence provided the basis for human trials using this system 22, 23 and brought up the issue of the potential role of the immune system in the rejection of grafted brain tumors. It was suggested that the bystander effect might have a role as an initial mechanism of tumor growth inhibition, but that an intact immune system is necessary to achieve an effective tumor rejection. 24 In addition to the controversy regarding the involvement of the immune system and the implications concerning ongoing and future clinical trials, recent work has questioned the real efficacy of HSVtk/GCV treatment. Tapscott et al demonstrated no significant survival difference between animals that received HSVtk/GCV treatment and those receiving vector alone. 25 Moreover, Santodonato et al reported in two different articles that the treatment of erythroleukemia tumors with HSVtk/ GCV induced only a transient inhibition in tumor growth. 26, 27 Furthermore, Cool et al reported no effect on tumor cell rejection following in vivo treatment of intracerebrally injected 9L cells with the HSVtk/GCV system. 28 To render tumor cells sensitive to GCV by HSVtk gene transfer, current approaches involve the use of viral and nonviral vectors. 1, 5, 6, 29 Alternatively, autologous transfer of in vitro-engineered cells has also been used. 30 Retroviral particles are labile and easily inactivated, and only low titers can be obtained. Therefore, the use of vector-producing cells (VPCs) has become an alternative for increasing the efficiency of in vivo transduction. Due to the controversial data from the literature regarding the efficacy of the HSVtk/GCV system, the role of the immune system in complete tumor cell rejection, and the possibility that part of the discrepancy may result from the use of different animal and tumor models and viral vectors, we decided to study the mechanism involved in in vivo tumor cell rejection following ex vivo and in vivo transduction of three different tumor cell types, using VPCs carrying the HSVtk gene followed by GCV treatment. For this purpose, we used murine B16 melanoma and C6 glioma cells injected in syngeneic immunocompetent animals and IIB-MEL-LES human melanoma cells injected in nude mice. The present data show that the antitumor efficacy of the HSVtk/GCV system following in vivo transduction varies in the different models and strongly suggest that an intact immune system plays a critical role in complete tumor cell rejection following HSVtk/GCV treatment.
MATERIALS AND METHODS

Cell lines
The IIB-MEL-LES cell line was established from a human metastatic melanoma and routinely grown as described previously. 31 The B16 murine melanoma (CRL 6323; American Type Culture Collection (ATCC), Manassas, Va) and the C6 rat glioma (CCL 107, ATCC) cell lines were routinely maintained in Dulbecco's modified Eagle medium (DMEM) containing 10% (v/v) fetal bovine serum, 2 mM glutamine, 2.5 U/mL penicillin, and 2.5 g/mL streptomycin. The amphotropic GPϩenvAm12 packaging cell line was maintained as described previously. 32 Recombinant retroviral construction, transfection of packaging cells, and harvesting of retroviral supernatants
The HSVtk gene was isolated from the plasmid Pago 33 as a 1.7-kilobase BglII-PvuII fragment. The pBabeNeo vector 34 was opened at EcoRI, and the site was blunted by filling in with Klenow and redigested with BamHI. The BglII-PvuII 1.7-kilobase fragment of HSVtk was subcloned inside the BamHIEcoRI-blunt sites of pBabeNeo. The resulting construct, named pAGOBabeNeo, has a restored EcoRI site at the joint of the blunt EcoRI with PvuII sites. A total of 20 g of the recombinant retroviral vector was used for the transfection of GPϩenvAm12 cells, by coprecipitation with calcium phosphate.
35 G418 (2 mg/mL)-resistant GPϩenvAm12 cell colonies were selected and pooled. Viral supernatants that had been harvested from confluent 9-cm plates after overnight incubation in 5 mL of medium containing newborn calf sera without the selecting drug were filtered through 0.45-m filters to eliminate cell debris and used immediately for target cell transduction or snap-frozen.
Retroviral transduction of target cells
IIB-MEL-LES, B16, and C6 cells were plated at 5 ϫ 10 5 cells per 9-cm plate 1 day before adding viral supernatant. Polybrene (Sigma, St. Louis, Mo) was added to the viral supernatant to 8 g/mL, and the target cells were exposed to 2 mL of viral supernatants. The viral supernatant was discarded after 4 hours at 37°C, and the plates were washed once with DMEM followed by the addition of fresh medium without retrovirus. Plates were grown for an additional 48 -72 hours, trypsinized, and split in several 9-cm plates. G418 (1 mg/mL)-resistant colonies were isolated by ring cloning or limiting dilution.
In vitro cytotoxicity of GCV and analysis of the bystander effect
To select the cell clones to be used for in vitro and in vivo experiments, the sensitivity of the different clones to GCV was determined. A total of 1 ϫ 10 3 cells corresponding to the different isolated clones were seeded in triplicate in 96-well culture plates in 200 L of DMEM plus 10% fetal bovine serum per well. At 24 hours after plating, GCV (kindly provided by Laboratorios Rontag, Buenos Aires, Argentina) at final concentrations of 0 -50 M was added to each well, and the cells were incubated for 7-10 days. Fresh medium containing GCV was supplied every 48 hours. At the end of the incubation period, the number of surviving cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide method. 36 A total of 15 G418-resistant B16-derived clones were tested, and 12 were sensitive to 50 M of GCV. One clone, B16-tk, was selected for additional studies (Ͻ10% viable cells at 5 M of GCV). Of the 15 G418-resistant, C6-derived clones tested, 9 were found to be sensitive to 50 M of GCV. One clone, C6-tk, was selected for additional studies (Ͻ10% viable cells at 50 M of GCV). Finally, 42 G418-resistant IIB-MEL-LES-derived clones were tested, but only 3 were sensitive to 50 M of GCV. One, LES-tk, was selected for additional studies (Ͻ15% viable cells at 50 M of GCV). To determine the bystander effect, selected clones were mixed with the corresponding parental cells at different ratios and plated at a final density of 0.6 ϫ 10 3 , 1 ϫ 
In vivo studies
Male C57BL/6 and NIH:s nude mice (8-to 11 weeks old) obtained from the National Commission of Atomic Energy (Buenos Aires, Argentina) were injected subcutaneously (s.c.) in the right flank with B16-tk and LES-tk cells, respectively, or with the respective controls. At 1 week after cell injection, GCV treatment was started at 25 mg/kg twice a day (b.i.d.) intraperitoneally (i.p.) in 0.1 mL of saline. Given the toxicity of this amount, nude mice were given i.p. injections of 12.5 mg/kg GCV under the same conditions. Tumor growth was evaluated every 2 days and measured in two perpendicular diameters with calipers. Each in vivo experiment contained six to eight animals per group. For the treatment of established C6 glioma tumors, C6 cells were injected stereotactically as described previously. At 5 days after the injection of C6 cells, mice were injected stereotactically with VPC-neo or VPC-producing retroviral vectors carrying the herpes simplex virus thymidine kinase gene (VPC-tk) cells at similar coordinates. GCV treatment was initiated 5 days later. Animals were housed and treated as described previously.
Histopathology and immunohistochemistry
Animals were sacrificed by cervical dislocation. Brains were dissected and fixed in paraformaldehyde/PBS, and the entire injection area was embedded in paraffin. Serial sections of 5 m were stained with hematoxylin and eosin. Immunohistochemical staining was performed on paraffin sections. Macrophages were identified with mouse anti-rat ED1/11 monoclonal antibody (mAb) (1/1000 dilution, Serotec, Oxford, UK). T cells were identified with anti-rat MRC OX-19 mAb (1/100, Serotec). Polymorphonuclear cells were identified with anti-rat HB199 mAb (1/2500 dilution, kindly provided by Dr. Hugh N. Perry, University of Oxford, Oxford, UK). Following deparaffinization through xylene, sections were incubated for 30 minutes in 1.0% H 2 O 2 in methanol and rehydrated through graded alcohols. After rinsing in PBS, sections were incubated with 10% normal goat sera in PBS for 15 minutes at room temperature followed by incubation with the primary mAb diluted in PBS. After overnight incubation at 4°C, sections were washed with PBS and incubated for 30 minutes with biotin-labeled goat anti-mouse immunoglobulin G (1/500 dilution, Jackson ImmunoResearch Laboratories, West Grove, Pa). Following PBS washings and incubations for 60 minutes with Vectastain ABC elite reagent (Vector Laboratories, Burlingame, Calif), staining was developed with diaminobenzidine. Sections were counterstained with hematoxylin.
Tissue samples obtained from tumors growing in nude mice were fixed, paraffin-embedded, and sectioned at 5 m. Human melanoma cells were identified using mouse anti-human HMB45 mAb and rabbit anti-S100 antisera (both from Dako, Hamburg, Germany). The reaction was developed using Vectastain reagents as described above.
Statistical analysis
The student t test, one-way analysis of variance, and TukeyKramer multiple comparison tests were used for the statistical analysis of in vitro and in vivo assays.
RESULTS
In vitro analysis of the bystander effect VPC-tk cells were obtained following the transfection of GPϩenvAm12 cells with the retroviral vector pAGOBabeNeo. Following retroviral transduction of the three tumor cell lines with a retrovirus carrying the HSVtk gene, clones resistant to G418 were selected according to their sensitivity to GCV. One sensitive clone from each cell line, selected as described in Materials and Methods, was designated LES-tk, B16-tk, and C6-tk, respectively. These cell clones, which were almost completely eliminated in the presence of a final concentration of 50 M of GCV, were used for additional in vitro and in vivo experiments.
To verify the strength of the in vitro bystander effect, C6-tk and C6 parental cells were mixed in different proportions. Cells were plated in 96-well plates at five different densities (see Materials and Methods). When a total of 5 ϫ 10 3 cells were plated, cells seemed to be in direct contact with neighboring cells; only 25% of C6-tk cells were necessary to eliminate Ͼ80% of total cells (Fig 1) . At lower densities of plated cells, most cells were sparse and not in contact with the neighboring cells at the time of exposure to GCV, and no bystander killing was observed (data not shown). Comparative studies performed with LES-tk and B16-tk cells showed no bystander effect regardless of cell density, although these clones were as sensitive as C6-tk to GCV (data not shown). In fact, B16-tk cells were eliminated completely at a concentration of 5 M of GCV (see Materials and Methods).
In vivo studies with B16 murine melanoma cells Our initial studies in vivo confirmed previous data, because mice injected with B16-tk cells and treated with GCV did not develop tumors, whereas those injected with B16-tk cells and treated with saline or injected with B16 cells and treated with GCV showed tumors of Ͼ1.5 cm 3 by day 31 (P Ͻ .01, Fig 2A) . The animals that rejected the injection of B16-tk cells remained free of tumors for Ͼ2 months (data not shown). When the efficacy of in vivo transduction of tumor cells using VPC-tk cells followed by GCV administration was assessed, we observed that mice coinjected with a mixture of B16 cells and VPC-tk cells showed a statistically significant decrease in mean tumor volume when treated with GCV compared with saline-treated mice (P Ͻ .01). However, this treatment was only partly efficient, because tumors developed in 100% of mice in both groups in two different experiments (Fig 2B) . Five mice coinjected with B16 cells and VPC-␤-galactosidase (␤-gal) and treated with GCV developed tumors that were superimposable in size compared with those observed in animals coinjected with B16 cells and VPC-tk and treated with saline (data not shown).
In vivo studies with IIB-MEL-LES human melanoma cells
The results obtained with the B16 murine melanoma model led us to studies aimed at establishing the efficacy of VPC-tk cells in the IIB-MEL-LES human melanoma model. Thus, six mice per group were injected with a tumorigenic inocula of 3 ϫ 10 6 IIB-MEL-LES cells mixed 1:1 with VPC-tk cells. Similar amounts of IIB-MEL-LES cells coinjected with VPC-␤-gal cells were used as a control. Following GCV treatment, the mean tumor volume in the control group after 20 days was 0.45 Ϯ 0.05 cm 3 , whereas in the group coinjected with IIB-MEL-LES and VPC-tk cells, the mean tumor volume was 0.05 Ϯ 0.02 cm 3 (mean Ϯ SD, P Ͻ .001 compared with the control group). At the same time, mice injected with VPC-tk cells without GCV treatment showed a mean tumor volume of 0.04 Ϯ 0.04 cm 3 . However, at the end of the experiment (50 days after the end of GCV injection), cell growth resumed in 100% of mice from the IIB-MEL-LES plus VPC-tk group, reaching a mean tumor volume of 2.1 Ϯ 0.3 cm 3 , compared with a mean tumor volume of 3.9 Ϯ 1.6 cm 3 for the control group. A histological and immunohistochemical analysis of tumors corresponding to mice coinjected with IIB-MEL-LES and VPC-tk cells, using antibodies against HMB45 and S100 melanoma antigens, showed the presence of both cell types. The capacity of VPC-tk cells to grow in nude mice once they escaped GCV treatment was supported by the fact that VPC-tk cells injected alone with no subsequent treatment with GCV did grow in nude mice (mean tumor volume of 2.6 Ϯ 0.99 cm 3 at the end of the experiment).
In vivo studies with C6 rat glioblastoma cells Previous data demonstrated that two different models of experimental melanoma may be rendered sensitive to GCV after in vivo transduction with VPC-tk cells. However, they also showed the limited efficacy of the HSVtk/ GCV system, because all of the animals developed tumors in both the murine and human experimental melanomas. For additional insight into the mechanisms involved in tumor rejection following HSVtk/GCV treatment, additional studies were performed using the C6 glioma experimental model with the same preparation of VPCs. In a short-term study, we found that none of the five rats that had been given an intracerebral injection of C6 cells followed by GCV treatment survived Ͼ22 days, whereas groups of five rats injected with either C6-tk or C6 plus VPC-tk cells and treated with GCV were alive and in good health. A histological examination of brains from C6 control rats showed typical large brain tumors with scarce mononuclear cells, with tumor mass completely filling the right hemisphere of the brain (Fig 3a) . The brains of the C6-tk group of rats showed no visible tumors, whereas those from rats injected with C6 plus VPC-tk revealed minimal residual tumors (Fig 3b) composed of nests of neoplastic cells surrounded and intermingled with an abundant infiltrate of immune cells (Fig  3c) . Immunohistochemical characterization of the infiltrate showed the presence of a high number of T lymphocytes and macrophages and few polymorphonuclear leukocytes (Fig 3, d and e) . Infiltrating immune cells were also found in the brain parenchyma surrounding the tumor sites and within the lumen of vessels in the periphery of the neoplastic nests (data not shown). The large infiltrate of immune cells following HSVtk gene transfer and GCV treatment led us to perform long-term experiments intended to establish the role of the immune system.
Following stereotactic transfer, six rats injected with C6 parental cells had a mean survival time of 20 Ϯ 4 days. No difference in survival time was found when five rats were injected with C6 plus VPC-neo cells (24 Ϯ 2 days), although an abundant infiltrate of mononuclear and polymorphonuclear cells was observed in this case (data not shown). This evidence suggests that the inflammatory infiltrate following xenogeneic grafting of murine VPCs was unable to affect tumor cell growth. Alternatively, rats injected with C6 plus VPC-tk cells and treated with GCV survived for average of 45 Ϯ 23 days, whereas a prolonged survival was observed in 50% (5 of 10) of the rats (P Ͻ .0001, Fig 4A) . Two rats that survived for 42 and 43 days showed no evidence of tumor mass in the brain and died for unknown reasons. Four rats from the long survival group were challenged with C6 cells in the left caudate nucleus 65 days after the first implantation of C6 cells. Two of these rats were sacrificed after 15 and 20 days, respectively, and an inflammatory infiltrate of T lymphocytes and macrophages was observed at the site of the challenge in the left hemisphere in both cases (data not shown). The remaining two rats were sacrificed 65 days postchallenge. Both brains were macroscopically clear of tumor cells in both hemispheres. In serial sections, we observed glial proliferation and disorganization as well as macrophages and T lymphocytes at the site of the challenge (Fig 3f) . All five naive rats that were used as controls did not survive Ͼ17 days and had macroscopic large tumor masses. The overall data demonstrated that VPC-tk injection followed by GCV was more effective in inducing a complete rejection of C6 tumors compared with B16 and IIB-MEL-LES experimental melanomas.
Finally, we evaluated whether HSVtk gene transduction followed by GCV treatment could cure rats with established C6 brain tumors. Following stereotactic transfer, six rats injected with C6 cells had a mean survival time of 26 Ϯ 6 days (Fig 4B) . Alternatively, 4 of 12 rats injected with C6 cells were cured by treatment with VPC-tk cells and GCV (P Ͻ .0001, Fig 4B) . The remaining eight rats developed tumors and died by 27 Ϯ 2 days. The four cured rats were challenged with C6 cells in the left caudate nucleus 80 days after the first tumor implantation. These rats rejected the challenge and remained alive until sacrifice at 55 days postchallenge. Histological studies demonstrated no evidence of tumor cells in both hemispheres. All three naive rats used as a controls did not survive for Ͼ28 days and had large tumor masses.
DISCUSSION
The present studies have demonstrated that the antitumor efficacy of the HSVtk/GCV suicide system varies depending upon the tumor cell model. A significant rejection of tumor cell growth and cure of tumor-bearing rats as well as a clear in vitro bystander effect was observed with the C6 model, whereas an inhibition of tumor growth but no in vitro bystander effect was observed with human and murine melanoma models. Rats that rejected C6 primary tumors were able to reject a subsequent challenge in the opposite flank of the brain with parental C6 cells, suggesting a key role for the immune system in inducing complete tumor rejection.
Recently, several reports have questioned the potential of the HSVtk/GCV system to induce tumor rejection. 26 -28,37 Moreover, it has been shown that the sole expression of the HSVtk gene or a marker gene in immunogenic cells such as 9L can induce rejection regardless of GCV treatment. 25 The present data clearly demonstrated no effect on tumor cell growth on the three cell lines unless tumor cells were transduced in vivo with VPC-producing retrovirus carrying the HSVtk gene and the animals were treated with GCV. We found no tumor cell rejection when mice injected with tumor cells carrying the HSVtk gene were treated with saline or when VPCs alone or VPC-producing retrovirus carrying nonspecific genes such as neo or ␤-gal were used. We also observed that the inflammatory response resulting from xenograft transplantation of murine VPCs in rat brains does not contribute to the immune-mediated antitumor effect, regardless of whether foreign antigens are expressed, because no survival improvement was observed in these cases compared with control rats. Thus, the present data support the notion that tumor cells can be rejected only following treatment with the complete HSVtk/GCV system.
In recent years, special attention has been focused on the possible role of the immune system in the complete eradication of tumor growth following treatment with HSVtk/GCV. Initial reports supported the notion that the immune system was not necessary for tumor rejection; 38, 39 however, recent evidence suggests that the complete elimination of tumor cells requires an intact immune system. 40, 41 Additional support for the involvement of the immune system came from studies showing that the complete regression of colon carcinomas and gliomas could be observed only in immunocompetent mice, but not in athymic mice. 42, 43 The present data confirm and extend a previous study using the 9L glioma model, 3 and demonstrate that rats that were able to completely reject C6 primary tumor growth following HSVtk/GCV treatment developed long-term antitumor immune memory against parental cells that involved T cells and macrophages. The development of an immune response was also observed in rats that were cured following vaccination with VPC-tk cells. Although we could not observe complete tumor rejection in any of the mice bearing murine and human melanoma tumors, previous data from the literature suggested that an immune reaction secondary to HSVtk/GCV treatment can develop in the B16 model. 10 However, contralateral vaccination of established B16 tumors with viable B16 cells expressing HSVtk followed by GCV treatment was ineffective in inhibiting B16 tumor growth, contrary to the vaccination with B16 cells expressing both HSVtk and interleukin-2. 44 Previous studies by Bonnekoh et al have also shown a 50% reduction in A375-SM human melanoma growth following in vivo transduction using adenoviral vectors carrying the HSVtk gene and GCV treatment. 45 Although A375-SM cells showed a strong in vitro bystander effect, similar studies demonstrated that other human melanoma cell lines can show a bystanderresistant phenotype similar to that observed with the IIB-MEL-LES cell line. 14 Recently, Ram et al reported the first results of a phase I clinical trial using the HSVtk/GCV system for gene therapy of brain tumors and argued against the involvement of the immune system. They suggested that most of the antitumor effect was the result of a nonimmune bystander effect. 46 However, it must be considered that these investigators did not study the immune response, which is in fact a secondary event following the initiation of GCV treatment. Indeed, the induction of antitumor-specific cytotoxic T lymphocytes 47 and an enhanced expression of the costimulatory molecules B7-1, B7-2, and intercellular adhesion molecule suggest that cell killing following treatment with HSVtk/GCV produces immunostimulatory signals, enabling the immune system of the host to recognize and eliminate the remaining tumor cells. 24, 48 The tendency of glioma tumors to extend through a diffuse local invasive pattern at distant sites into the central nervous system, 49 the broad suppression of humoral and cell-mediated immunity during the development of human gliomas, 50 the fact that the central nervous system is considered to be an immunologically privileged site, 51 and the limitations of the vectors available for efficient gene delivery make the augmentation of the immune response following HSVtk/GCV treatment an important strategy to achieve complete tumor rejection. The lack of complete tumor rejection of human and murine melanoma cells in the present studies and previous data from the literature also stressed the importance of the immune system in achieving total tumor rejection. These results are rather important when extrapolating the data from animal models to human brain tumors that are less immunogenic and show a decreased immunity compared with the currently used experimental brain tumors. 50 Therefore, studies aiming at augmenting the immune response elicited by the HSVtk/GCV system (for instance, by combining it with cytokine gene expression), although not effective in all cases, 26, 38, 51, 52 might be an alternative to enhance tumor recognition and its rejection by the immune system of the host.
